YARAL Pharma Marks Its First Anniversary

Press Release

Quality Products, Innovative Technology, and Exceptional Customer Service Characterize a Successful Inaugural Year

YARAL Pharma Inc., (YARAL Pharma) is proud to celebrate the first anniversary of its entry into the United States generics marketplace. YARAL Pharma is the U.S. generics subsidiary of IBSA (Institut Biochimique SA), a distinguished multinational pharmaceutical company headquartered in Lugano, Switzerland. During its first year, the company has consistently lived up to its mission of delivering affordable, high-quality authorized and complex generic medications.

"Our journey over the past year has been marked by significant accomplishments," said Stephen Beckman, CEO of YARAL Pharma. "Drawing inspiration from our parent company, we have launched multiple products, harnessed innovative technologies, and upheld exceptional levels of customer service. We are proud to be a significant contributor among IBSA’s global, commercial subsidiaries and are excited by the remarkable progress our team has achieved in expanding access to our products.”

Luca Crippa, CCO of IBSA Group added, “YARAL Pharma has done an excellent job of establishing a strong foothold in the U.S. generics industry while maintaining IBSA’s decades-long track record of product quality, manufacturing expertise, and commitment to innovation.”

Notable Achievements
Under the leadership of industry veterans, YARAL Pharma has successfully launched products from IBSA’s pipeline of authorized generics (AG) beginning with Diclofenac Epolamine Topical System 1.3% in early 2023. This launch was followed by the introduction of Levothyroxine Sodium Capsules and Lidocaine Patch 5%.

The company has also made great strides in expanding access to its products across the U.S. and its territories. YARAL Pharma supports its regional and national partners including independent pharmacies, long-term care facilities, grocery chains, distributors, and wholesalers, servicing almost 96% of their patients’ and government entities’ needs, with an average on-time shipping rate of 90%, ensuring timely delivery of its products to all its partners.

“In a changing generics industry landscape, YARAL Pharma remains resilient and continues to thrive,” added Beckman. “Success is now defined by having the right products in your portfolio rather than the most. YARAL Pharma's growth trajectory remains strong, with plans to continually expand its product offerings and therapeutic areas through strategic external partnerships and opportunities.”

For the latest updates on YARAL Pharma and its innovative offerings, please visit www.yaralpharmainc.com or connect with the company on LinkedIn.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.